Survival Following Cardiac Transplantation in Patients with Hypertrophic Cardiomyopathy.

06:00 EDT 26th August 2010 | BioPortfolio

Summary of "Survival Following Cardiac Transplantation in Patients with Hypertrophic Cardiomyopathy."

-Heart transplant is a treatment for selected patients with hypertrophic cardiomyopathy (HCM). However, the prevalence, clinical profile and outcome of this subgroup of HCM patients are uncertain. Therefore, we sought to determine the occurrence, clinical characteristics and prognosis of HCM patients who underwent cardiac transplantation in the United States during a 15-year period. METHODS AND
-Demographic, clinical and survival outcome of 26,706 adult (age >/=18 years) heart-only transplant recipients between January 1990 to December 2004 were acquired from the United Network of Organ Sharing (UNOS) Registry. Pre-transplant diagnoses were classified as: HCM (n=303; 1%) and non-HCM (26,403; 99%) [comprised of threepatient subgroups: 1) ischemic cardiomyopathy (n=14,308; 54%); 2) dilated cardiomyopathy (n=11,760; 44%); and 3) restrictive cardiomyopathy (n=335; 1%)]. Study follow-up began at the time of heart transplant and was 76+/-44 months among survivors. The 1-, 5-, and 10-year overall transplant survival for HCM patients was 85%, 75%, and 61%, with a trend toward greater survival compared to non-HCM transplant patients (82%, 70%, 49%; log rank test, p=0.05). However, propensity matched, covariate-adjusted Cox regression model analysis showed better survival over time (p<0.01) among the HCM patients. When HCM post-transplant survival was compared to each of the non-HCM patient subgroups, HCM patients had more favorable survival than those transplanted for ischemic cardiomyopathy (p=0.02). In contrast, HCM post-transplant survival did not differ from those patients transplanted for restrictive (p=0.08) or dilated cardiomyopathy (p=0.25).
-HCM patients comprise a small subset (1%) of the overall population of patients who undergo heart transplantation in the United States. Nonetheless, survival following transplant among HCM patients is comparable to patients transplanted for non-HCM cardiovascular diseases, with possible enhanced survival over time.


1 Hypertrophic Cardiomyopathy Center, Division of Cardiology, Tufts Medical Center, Boston, MA;

Journal Details

This article was published in the following journal.

Name: Circulation. Heart failure
ISSN: 1941-3297


DeepDyve research library

PubMed Articles [36070 Associated PubMed Articles listed on BioPortfolio]

The Role of Human Urotensin-II in Patients with Hypertrophic Cardiomyopathy.

Hypertrophic cardiomyopathy (HCM) is a genetic condition with the hallmark feature of left ventricular hypertrophy. Human Urotensin-II (hUT-II) is regarded as a cardiovascular autacoid/hormone, and it...

The role of cardiovascular magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Part II.

Hypertrophic cardiomyopathy is currently understood as a group of diseases with left ventricular hypertrophy, which are not based on adaptive mechanisms. The first part of the review details the possi...

Hypertrophic cardiomyopathy in the adolescent.

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, which generally manifests during adolescence. Adolescents may be diagnosed incidentally, following the investigation of ...

Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models.

In cardiomyocytes from patients with hypertrophic cardiomyopathy, mechanical dysfunction and arrhythmogenicity are caused by mutation-driven changes in myofilament function combined with excitation-co...

Procedural complication and long term outcomes after alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: data from China.

Data on procedural complications and long term survival after alcohol septal ablation (ASA) in Chinese patients with obstructive hypertrophic cardiomyopathy (HOCM) are lacking. We aimed to investigate...

Clinical Trials [7803 Associated Clinical Trials listed on BioPortfolio]

The Chinese Hypertrophic Cardiomyopathy Study(CHCS)

Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, with a prevalence of ∼0.2%. The disease affects all age groups, with marked clinical heterogeneity...

Insertable Cardiac Monitors in Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is associated with sudden cardiac death and an increased risk of atrial fibrillation and subsequent embolic event. An insertable cardiac monitor will prov...

Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathy

Patients with hypertrophic cardiomyopathy are being compared to a control group. IMR will be assessed with a pressure wire. Clinical f/u at 3 months and 6 months and a 48 hour holter monit...

Multicenter Exploratory Study of Accelerometry in Hypertrophic Cardiomyopathy

Study evaluate the relationships between daily physical activity levels (PAL) and functional capacity (VO2peak) in patients with hypertrophic cardiomyopathy (HCM)

Use of Magnetic Field Mapping in the Evaluation of Patients With Hypertrophic Heart Disease (Thick Heart Muscle)

The purpose of this research study is to further establish the diagnostic use of magnetocardiography (MCG) in patients with hypertrophic cardiomyopathy (HCM). The use of MCG has not been ...

Medical and Biotech [MESH] Definitions

An autosomal dominant inherited form of HYPERTROPHIC CARDIOMYOPATHY. It results from any of more than 50 mutations involving genes encoding contractile proteins such as VENTRICULAR MYOSINS; cardiac TROPONIN T; ALPHA-TROPOMYOSIN.

A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).

A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).

One of the three polypeptide chains that make up the TROPONIN complex. It is a cardiac-specific protein that binds to TROPOMYOSIN. It is released from damaged or injured heart muscle cells (MYOCYTES, CARDIAC). Defects in the gene encoding troponin T result in FAMILIAL HYPERTROPHIC CARDIOMYOPATHY.

Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.

Quick Search

DeepDyve research library

Relevant Topics

Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Searches Linking to this Article